KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Net Income - Minority (2017 - 2020)

Historic Net Income - Minority for BeOne Medicines (ONC) over the last 4 years, with Q3 2020 value amounting to -$19.6 million.

  • BeOne Medicines' Net Income - Minority fell 2436.7% to -$19.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$19.6 million, marking a year-over-year decrease of 2436.7%. This contributed to the annual value of -$16.2 million for FY2019, which is 1180.34% down from last year.
  • According to the latest figures from Q3 2020, BeOne Medicines' Net Income - Minority is -$19.6 million, which was down 2436.7% from -$10.2 million recorded in Q2 2020.
  • In the past 5 years, BeOne Medicines' Net Income - Minority ranged from a high of -$10.2 million in Q2 2020 and a low of -$19.6 million during Q3 2020
  • Its 4-year average for Net Income - Minority is -$15.0 million, with a median of -$14.6 million in 2018.
  • The largest annual percentage gain for BeOne Medicines' Net Income - Minority in the last 5 years was 4137.0% (2020), contrasted with its biggest fall of 2436.7% (2020).
  • Quarter analysis of 4 years shows BeOne Medicines' Net Income - Minority stood at -$14.4 million in 2017, then fell by 0.16% to -$14.4 million in 2018, then decreased by 11.8% to -$16.2 million in 2019, then dropped by 21.36% to -$19.6 million in 2020.
  • Its Net Income - Minority stands at -$19.6 million for Q3 2020, versus -$10.2 million for Q2 2020 and -$14.8 million for Q1 2020.